News

Feb 02, 2022
Genetic Engineering & Biotechnology News – Bitter Taste Receptors Represent a Therapeutic Sweet Spot
Feb 02, 2022
Aardvark Therapeutics, Inc., Announces the Initiation of Enrollment For Three Phase 2 Clinical Trials of Oral ARD-101
Jan 10, 2022
Aardvark Therapeutics, Inc., Announces it has been Invited to Present at the 40th Annual J.P. Morgan Health Care Conference
Aug 05, 2021
Emerging from stealth mode, Aardvark rounds up enough cash to put its lead drug through Prader-Willi PhII
Aug 05, 2021
Aardvark Therapeutics, Inc., Completes $29M Series B Funding Led by Sorrento Therapeutics and Including Existing Investors and the Foundation for Prader-Willi Research
Mar 01, 2021
Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome
Dec 02, 2020
Aardvark Therapeutics, Inc., to Present at the 32nd Annual Piper Sandler Healthcare Conference
Nov 02, 2020
Aardvark Therapeutics, Inc., Announces Poster Presentations at the 2020 Obesity Week Conference
Oct 15, 2020
Aardvark Therapeutics, Inc., Announces Completion of First Cohort in Phase I for ARD-101
Nov 29, 2019
Aardvark Therapeutics, Inc., Completes $15M Series A Funding Co-Led by Vickers Venture Partners and Premier Partners
Company Presentations